Research has continued on the preparation of a hemostatic agent in the form of a lyophilized sponge composed of chitosan glutamate and collagen. Characterization of the chitosan glutamate raw material has progressed; levels of metal and amino acid contamination were determined. Work was also initiated on the in vitro degradation of chitosan glutamate by lysozyme. Over 25 sample compositions 3f various chitosan glutamate/collagen sponges were evaluated for wet and dry strength, handling characteristics, and hemostatic activity in a rat bleeding sagittal sinus model. From these samples, two compositions were identified for further testing. Semex Medical was identified as the manufacturer of the sponge samples.. glutamate, 3M will rely on the vendor's determination. 3M will, however, try to secure retain samples of the chitosan free base of each lot so that an independent determination of the percent deacetylation will be possible. His group has initiated some work on molecular weight determination of chitosans using chromatographic techniques. His experience thus far is that chitosan non-specifically binds to standard chromatographic separation media so that no reproducible and reliable information can be gained using standard techniques. This is similar to the results that 3M had obtained early in our work with chitosan.
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3M is, therefore, not actively pursuing the accurate determination of chitosan molecular weights. Smidsrod anticipates initiation of a research program directed at this problem, and 3M will stay in contact with him to keep abreast of all the latest developments. As was shown earlier, the molecular weight of chitosan (as long as it's above an empirically determined minimum)
has only a minimal effect on the time to stable coagulum formation in vitro.
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Therefore, 3M will continue to monitor molecular weight of samples with intrinsic viscosity measurements to ensure that samples are of sufficient molecular weight to coagulate blood. When more precise methods become available, 3M will incorporate them into its testing scheme.
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Task 2: Formulation and Optimization
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As described in the last quarterly report, the hemostatic agent is a lyophilized sponge composed of chitosan glutamate and collagen. Although 3M
has continued to make a limited number of trial compositions in our laboratory, it has been decided to utilize Semex Medical as the source for all prototype lyophilized sponge compositions. This decision was based on 
U
Task 7: Sponge Manufacturing Scale-Up and Process Validation
The decision to utilize Semex medical as the supplier of the lyophilized final product sponge significantly affects the ease with which Task 7 will be completed during years two and three of the contract. The prototype sponges are being prepared by Semex with processes which are known to be applicable to larger scale manufacturing. The scale-up and process validation for this product, therefore, should be rather uncomplicated and not require as long as originally anticipated in the original proposal.
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This also results in 3M testing prototype products with the added assurance that any composition can be scaled-up, if appropriate. 
